These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34876673)

  • 1. Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.
    Chen V; Umemura S; Han Y; Raman R; Tucker R; Chahine J; Kim IK; Schatz C; Zitzmann-Kolbe S; Sommer A; Onda M; Lee T; He Y; Giaccone G
    Br J Cancer; 2022 Mar; 126(5):754-763. PubMed ID: 34876673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
    Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
    Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
    Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
    J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.
    Bellissimo T; Ganci F; Gallo E; Sacconi A; Tito C; De Angelis L; Pulito C; Masciarelli S; Diso D; Anile M; Petrozza V; Giangaspero F; Pescarmona E; Facciolo F; Venuta F; Marino M; Blandino G; Fazi F
    Mol Cancer; 2017 May; 16(1):88. PubMed ID: 28486946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells.
    Lazzerini L; Jöhrens K; Sehouli J; Cichon G
    Arch Gynecol Obstet; 2020 Nov; 302(5):1255-1262. PubMed ID: 32815024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
    Quanz M; Hagemann UB; Zitzmann-Kolbe S; Stelte-Ludwig B; Golfier S; Elbi C; Mumberg D; Ziegelbauer K; Schatz CA
    Oncotarget; 2018 Sep; 9(75):34103-34121. PubMed ID: 30344925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
    Santin AD; Vergote I; González-Martín A; Moore K; Oaknin A; Romero I; Diab S; Copeland LJ; Monk BJ; Coleman RL; Herzog TJ; Siegel J; Kasten L; Schlicker A; Schulz A; Köchert K; Walter AO; Childs BH; Elbi C; Bulat I
    Int J Gynecol Cancer; 2023 Apr; 33(4):562-570. PubMed ID: 36564099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesothelin as a target for cervical cancer therapy.
    Jöhrens K; Lazzerini L; Barinoff J; Sehouli J; Cichon G
    Arch Gynecol Obstet; 2019 Jan; 299(1):211-216. PubMed ID: 30324544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LOXL1‑AS1 promotes thymoma and thymic carcinoma progression by regulating miR‑525‑5p‑
    Wang J; Huang H; Zhang X; Ma H
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33907842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of mesothelin in thymic carcinoma and its potential therapeutic significance.
    Thomas A; Chen Y; Berman A; Schrump DS; Giaccone G; Pastan I; Venzon DJ; Liewehr DJ; Steinberg SM; Miettinen M; Hassan R; Rajan A
    Lung Cancer; 2016 Nov; 101():104-110. PubMed ID: 27794397
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Roy J; Jagoda EM; Basuli F; Vasalatiy O; Phelps TE; Wong K; Ton AT; Hagemann UB; Cuthbertson AS; Cole PE; Hassan R; Choyke PL; Lin FI
    Cancer Biother Radiopharm; 2021 May; 36(4):316-325. PubMed ID: 34014767
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
    Mansfield AS; Vivien Yin J; Bradbury P; Kwiatkowski DJ; Patel S; Bazhenova LA; Forde P; Lou Y; Dizona P; Villaruz LC; Arnold SM; Khalil M; Kindler HL; Koczywas M; Pacheco J; Rolfo C; Xia B; Mikula E; Chen L; Patel K; Smith KER; Cao L; Shapiro G; Costello BA; Adjei A; Sharon E; Moscow JA; Zamboni W; Hassan R
    Lung Cancer; 2024 Sep; 195():107928. PubMed ID: 39197359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the mTOR/ Akt pathway in thymic epithelial cells derived from thymomas.
    Maury JM; Merveilleux du Vignaux C; Drevet G; Zarza V; Chalabreysse L; Maisse C; Gineys B; Dolmazon C; Tronc F; Girard N; Leroux C
    PLoS One; 2019; 14(3):e0197655. PubMed ID: 30897085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
    Wang Y; Nie J; Dai L; Hu W; Chen X; Han J; Ma X; Tian G; Han S; Long J; Zhang Z; Fang J
    Thorac Cancer; 2019 Jan; 10(1):17-23. PubMed ID: 30411854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.
    Hsu HJ; Tung CP; Yu CM; Chen CY; Chen HS; Huang YC; Tsai PH; Lin SI; Peng HP; Chiu YK; Tsou YL; Kuo WY; Jian JW; Hung FH; Hsieh CY; Hsiao M; Chuang SS; Shen CN; Wang YA; Yang AS
    Sci Rep; 2021 Jul; 11(1):15430. PubMed ID: 34326410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma.
    Khoury T; Chandrasekhar R; Wilding G; Tan D; Cheney RT
    Int J Exp Pathol; 2011 Apr; 92(2):87-96. PubMed ID: 21044186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.
    Alberobello AT; Wang Y; Beerkens FJ; Conforti F; McCutcheon JN; Rao G; Raffeld M; Liu J; Rahhal R; Zhang YW; Giaccone G
    J Thorac Oncol; 2016 Aug; 11(8):1345-1356. PubMed ID: 27117832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice.
    Zhang J; Bera TK; Liu W; Du X; Alewine C; Hassan R; Pastan I
    PLoS One; 2014; 9(8):e104388. PubMed ID: 25118887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer.
    Liang Z; Dong J; Yang N; Li SD; Yang ZY; Huang R; Li FJ; Wang WT; Ren JK; Lei J; Xu C; Wang D; Wang YZ; Liang ZQ
    Int J Biol Sci; 2021; 17(15):4365-4376. PubMed ID: 34803504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular aspects of thymic carcinoma.
    Weissferdt A; Wistuba II; Moran CA
    Lung Cancer; 2012 Nov; 78(2):127-32. PubMed ID: 22921473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.